NCT03248037

Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 120 (actual)
• Sponsor: Cornea Research Foundation of America · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.

Conditions

• Fuchs' Endothelial Dystrophy
• Bullous Keratopathy

Interventions

Type	Name	Description
DRUG	Netarsudil	netarsudil opthalmic solution 0.02%
DRUG	Placebo	Placebo eye drops

Timeline

• Start date: 2017-09-05
• Primary completion: 2019-07-09
• Completion: 2019-07-09
• First posted: 2017-08-14
• Last updated: 2021-02-12
• Results posted: 2021-02-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study